In fact, in some models, the anti-tumour activity of lysate-based vaccines is CD4+ T cell mediated [43], [44], including our studies of a glioma vaccine similar to the one used here [45], suggesting there may be a significant cohort of CD4+ T cells capable of providing protection against DC elimination. This evidence concerns the gene CD4 and central nervous system cancer.